Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 12/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.47 |
| ▸ | PIK3C2G | O75747 | 2/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.41 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21929800 | 1.00 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3C2B | |
| SCHEMBL22440910 | 0.89 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL22440911 | 0.89 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL29278873 | 0.85 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3C2B | |
| SCHEMBL21931557 | 0.85 | PIK3CG (0.37) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3C2B | |
| SCHEMBL21931555 | 0.85 | PIK3CG (0.37) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3C2B | |
| SCHEMBL29314155 | 0.85 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3C2B | |
| SCHEMBL29314147 | 0.85 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL29278904 | 0.85 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL21929750 | 0.84 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2022-10-27 | — | — | US | disclosed |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2020102216-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102198-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102150-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CA 4/4885 |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | PIK3CG 4/4885PIK3CD 1/4885PIK3CA 3/4885 |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | PIK3CG 4/4885PIK3CD 1/4885PIK3CA 3/4885 |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CA 2/4885 |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CA 4/4885 |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CA 2/4885 |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CA | PIK3CG 4/4885PIK3CD 1/4885PIK3CA 3/4885 |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CA | PIK3CG 4/4885PIK3CD 1/4885PIK3CA 3/4885 |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.